Author(s):
Urvashi N Patil, Sameer R Shaikh, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh
Email(s):
patilurvashi778@gmail.com , azamph46@gmail.com
DOI:
10.52711/2231-5691.2025.00054 
Address:
Urvashi N Patil1, Sameer R Shaikh1, Divakar R. Patil1, Akash S. Jain1, Azam Z. Shaikh2
1Bachelor of Pharmacy, P.S.G.V.P. M’s College of Pharmacy, Shahada.
2Assistant Professor, Department of Pharmaceutics, P.S.G.V.P. M’s College of Pharmacy, Shahada, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2025
ABSTRACT:
cystic fibrosis (CF) develop multilobular cirrhosis. Later on, the majority of CF patients experience problems from portal hypertension, primarily varicealhemorrhage. Liver failure typically strikes later in life, following childhood. It is advised to screen for liver disease every year in order to identify any presymptomatic indicators and to start ursodeoxycholic acid therapy, which may slow the illness's course. If two or more of the following criteria are met: abnormal physical examination, consistently abnormal liver function tests, and pathological ultrasonography, liver disease should be suspected. A liver biopsy is necessary if the diagnosis is unclear. Annual follow-up is necessary for all CF patients with liver disease to assess the onset of cirrhosis, portal hypertension, or liver failure. The goals of management should be on nutrition, hemorrhage control, andvariceal disintegration. When considering liver transplantation, deterioration of pulmonary function is crucial, especially in adolescents with severe portal hypertension or hepatic dysfunction. A hereditary disorder that impacts a protein in the body is known as cystic fibrosis (CF). A defective protein that affects the body's tissues, glands that produce sweat and mucus, and cells is what causes cystic fibrosis.
Cite this article:
Urvashi N Patil, Sameer R Shaikh, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh. Understanding Cystic Fibrosis: Causes, Symptoms, and Treatment Strategies. Asian Journal of Pharmaceutical Research. 2025; 15(3):347-2. doi: 10.52711/2231-5691.2025.00054
Cite(Electronic):
Urvashi N Patil, Sameer R Shaikh, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh. Understanding Cystic Fibrosis: Causes, Symptoms, and Treatment Strategies. Asian Journal of Pharmaceutical Research. 2025; 15(3):347-2. doi: 10.52711/2231-5691.2025.00054 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2025-15-3-18
REFERENCE:
1. National Heart, lung, and blood institiye An official website of the United States Government
2. Christie DA, Tansey EM (2004) Cystic Fibrosis. In: Christie DA, Tansey EM (eds) (2004) Wellcome Witnesses to Twentieth Century Medicine. Volume 20. London: The Wellcome Trust Centre for the History of Medicine at UCL, this volume. ISBN 0 85484 086 9.
3. Blackfan KD, Wolbach SB. Vitamin A deficiency in infants. Journal of Paediatrics. 1933; 3: 679-706.
4. Fanconi G, Uehlinger E, Knaver C. Das Coeliac syndrome bei Angeborenerzysticherpankre as fibromatose und bronchiektasen. Wien Medizinische Wochenschrift. 1936; 86: 753-756.
5. Fanconi G. Der intestinaleinfantilismus und ähnlicheformen der chronischenVerdauungsstörung. Bibliotheca Paediatrica. 1928; 21. Link: https://goo.gl/iFvYhQ
6. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathologic study. American Journal of Diseases of Children. 1938; 56: 344-399. Link: https://goo.gl/85yC15
7. Andersen DH. The present diagnosis and treatment of cystic fibrosis. Proc Roy Soc Med. 1949; 42: 25-31.
8. Farber S. Pancreatic insufficiency and the celiac syndrome. 1943; 229: 653-682. Link: https://goo.gl/tcHi8t
9. Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ. British Journal of Experimental Pathology. 1929; 10: 226-236. Link: https://goo.gl/zZh3c9
10. Andersen DH, Hodges RC. Celiac syndrome. Genetics of cystic fibrosis of the pancreas with consideration of the etiology. Am J Dis Child. 1946; 72: 62-80. Link: https://goo.gl/FkLXcJ
11. Bodian M. Fibrocystic Disease of the Pancreas: A Congenital Disorder of Mucus Production-Mucosis. Heinemann, London. 1952 Link: https://goo.gl/rg2B8b
12. Di Sant’Agnese PA, Andersen DH. Celiac syndrome. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulphonamide groups, with special reference to penicillin aerosol. American Journal of Diseases of Children. 1946; 72: 17-61. Link: https://goo.gl/xusQPy
13. Darling RC, Di Sant’Agnese PA, Perera GA, Andersen DH. Electrolyte abnormalities of sweat in fibrocystic disease of pancreas. American Journal of Medical Science. 1953; 225: 67-70. Link: https://goo.gl/YreU7i
14. Di Sant’Agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas: Clinical significance and relationship to the disease. Pediatrics. 1953; 12: 549-563. Link: https://goo.gl/PyygMt
15. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics. 1953; 23: 545-549.
16. Shwachman H, Kulczycki LL (1958) Long term study of one hundred five patients with cystic fibrosis. Am J Dis Child. 96: 6-15. Link: https://goo.gl/D7K1GL
17. Stollar F, VillacAdde F, Cunha MT, Leone C, Rodrigues JC (2011) Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity. Clinics. 66: 979–983. Link: https://goo.gl/dBXGLc
18. Bishop HC, Koop CE (1957) Management of meconium ileus, resection, Roux-en-Y anastomosis and ileostomy irrigation with pancreatic enzymes. Ann Surg. 145: 410-414. Link: https://goo.gl/zUJfsz
19. Noblett HR (1969) Treatment of uncomplicated meconium ileus by gastrografin enema. A preliminary report. J PediatrSurg. 4: 190-197. Link: https://goo.gl/pH2Dsc
20. Steinberg AG, Shwachman H, Allen FH, Dooley RR. Linkage Studies with Cystic Fibrosis of the Pancreas. Am J Hum Genet. 1956; 8: 162-166. Link: https://goo.gl/4yYQPC
21. Conneally PM, Merritt AD, Yu PL Tex Rep Biol Med. 1973; 31: 639-650.
22. Knowles M, Gaztzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. NEngl J Med. 1981; 305: 1489-1495. Link: https://goo.gl/oS7LsS
23. Quinton PM. Chloride impermeability in cystic fibrosis. Nature. 1983; 301: 421-422. Link: https://goo.gl/bYHcUY
24. Quinton PM, Bijman J. Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. N Engl J Med. 1983; 308: 1185-1189. Link: https://goo.gl/LnD9By
25. Tsui LC, Buchwald M, Barker D, Braman JC, Knowlton R, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science. 1985; 230: 1054-1057. Link: https://goo.gl/NwA6Ky
26. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.Science 245: 1066-1073. Link: https://goo.gl/Nd7cWd
27. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245: 1059-1065. Link: https://goo.gl/ktY8pj
28. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989; 245: 1073-1080. Link: https://goo.gl/hmMmHM
29. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991; 253: 202-205. Link: https://goo.gl/jbcY7y
30. Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, et al. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell. 1991; 67: 775-784. Link: https://goo.gl/PhRMfb
31. Scholte BJ, Davidson DJ, Wilke M, De Jonge HR. Animal modelsofcysticfibrosis. JournalofCystic Fibrosis. 2004; 3: 183-190. Link: https://goo.gl/VaYBHM
32. Snouwaert JN, Brigman KK, Latour AM. An animal model for cystic fibrosis made by gene targeting. Science. 1992; 257: 1083. Link: https://goo.gl/qaWfhc
33. Clarke LL, Grubb BR, Gabriel SE. Defective epithelial chloride transport in a gene targeted mouse model of cystic fibrosis Science. 1992; 257: 1125-1128. Link: https://goo.gl/nv4NRJ
34. Dorin JR, Dickinson P, Alton EW. Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature.1992; 359: 211-215. Link: https://goo.gl/Tr7Vy7
35. Ratcliff R, Evans MI, Cuthbert AW. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat. Genet. 1993; 4: 35-41. Link: https://goo.gl/FHBJ19
36. Kent G, Iles R, Bear CE. lung disease in mice with cysticfibrosis. J Clin Invest. 1997; 100: 3060-3069. Link: https://goo.gl/RQu3jp
37. Mall M. Overexpression of ENaC in mouse aiways: a novel animal modelforchronicbronchitis and cystic fibrosis lungdisease. PediatrPulmonol. 2003; 121: 137.
38. Medically reviewed by Adithya Cattamanchi. Pulmonology — Written by Stephanie Watson on August 7, 2019
39. Medically reviewed by Mia Armstrong— Written by Catherine Crider on September 14, 2023
40. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros. 2004; 3:209–222.
41. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000; 162: 891–895.
42. Limoli D, Yang J, Khansaheb M, et al. Staphylococcus aureus and pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. Eur J ClinMicrobiol Infect Dis. 2016; 35: 947–953.
43. Van Sambeek L, Cowley ES, Newman DK, Kato R. Sputum glucose and glycemic control in cystic fibrosis-related diabetes: a cross-sectional study. PLoS ONE. 2015; 10: e0119938.
44. Garnett JP, Kalsi KK, Sobotta M, et al. Hyperglycaemia and pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion. Sci Rep. 2016; 6:37955.
45. Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology and prognostic implications of cystic fibrosis-related diabetes. Diabetes Care. 2010; 33: 2677–2683.
46. Cystic Fibrosis Trust. Management of Cystic Fibrosis Related Diabetes Mellitus. London: Cystic Fibrosis Trust; 2004.
47. Chillón M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995; 332(22): 1475‐1480.
48. Sueblinvong V, Whittaker LA. Fertility and pregnancy: common concerns of the aging cystic fibrosis population. Clin Chest Med. 2007;28(2):433‐443.
49. Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr. 1992; 120(4 Pt 1): 533‐540.
50. Ledder O, Haller W, Couper RT, Lewindon P, Oliver M, et al. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J GastroenterolHepatol. 2014; 29(12): 1954‐1962.
51. Tan S, Coffey MJ, Ooi CY. Differences in clinical outcomes of paediatric cystic fibrosis patients with and without meconium ileus. J Cyst Fibros. 2019; 18(6): 857‐862.
52. Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Phoenix/ Scottsdale, Arizona, and Mayo Clinic in Jacksonville, Florida, have been recognized among the top Pulmonology hospitals in the nation for 2024-2025 by U.S. News & World Report.